KMT2B
protein-codinglysine methyltransferase 2B, the group of PHD finger proteins|SET domain containing|Zinc fingers CXXC-type|Lysine methyltransferases
Gene summary
This gene encodes a protein which contains multiple domains including a CXXC zinc finger, three PHD zinc fingers, two FY-rich domains, and a SET (suppressor of variegation, enhancer of zeste, and trithorax) domain. The SET domain is a conserved C-terminal domain that characterizes proteins of the MLL (mixed-lineage leukemia) family. This gene is ubiquitously expressed in adult tissues. It is also amplified in solid tumor cell lines, and may be involved in human cancer. Two alternatively spliced transcript variants encoding distinct isoforms have been reported for this gene, however, the full length nature of the shorter transcript is not known. [provided by RefSeq, Jul 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~20.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0015004
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0015004
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0015004
Submitter: Genomics England PanelApp
Inheritance Pattern: Unknown
Disease ID:MONDO:0030969
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0100516
Submitter: ClinGen
*KMT2B* was first reported in relation to Dystonia 28, childhood-onset and autosomal dominant intellectual developmental disorder in 2018 (Faundes et al., PMID: 29276005). Probands with dystonia have variable presentations and do not all present with intellectual disability. Additionally, some probands with intellectual disability and no dystonia phenotype share their variant with family members who present with dystonia but mild or no intellectual disability.Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found differences in phenotypic variability. However, the phenotypic differences were determined to be a spectrum of disease rather than two distinct entities. Therefore, the following disease entities, Dystonia 28, childhood-onset and intellectual developmental disorder, autosomal dominant 68, have been lumped into one disease entity, complex neurodevelopmental disorder with motor features. Ten variants (missense, nonsense, and frameshift) that have been reported in 10 probands in 2 publications (PMIDs: 29276005, 33150406) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached.The mechanism of pathogenicity is reported to be LOF. This gene-disease relationship is also supported by a non-human animal model (PMID: 23426673). Mice lacking *KMT2B* gene in adult forebrain excitatory neurons display impaired hippocampus-dependent memory function. In summary, there is definitive evidence to support the relationship between *KMT2B* and autosomal dominant complex neurodevelopmental disorder with motor features. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the Intellectual Disability and Autism Gene Curation Expert Panel on April 17, 2023 (SOP 9).
Inheritance Pattern: AD
Disease ID:MONDO:0015004
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0015004
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0015004
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Musculoskeletal; Neurologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
Comments: In Dystonia 28, surgical treatment (with deep brain stimulation) has been reported as effective
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to KMT2B variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_014727.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 11 | 509 | 133 | 654 | |
| missense | 1 | 38 | 1008 | 424 | 78 | 1549 |
| nonsense | 15 | 17 | 4 | 36 | ||
| start loss | 1 | 1 | ||||
| frameshift | 63 | 25 | 2 | 90 | ||
| splice donor/acceptor (+/-2bp) | 4 | 6 | 18 | 1 | 29 | |
| Total | 83 | 87 | 1043 | 934 | 212 | 2359 |
Highest pathogenic variant AF is 0.000009313291
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_055542.1 | 37 | MANE Select | |
| Ensembl | ENSP00000398837.2 | 37 | MANE Select | |
| Ensembl | ENSP00000501283.1 | 37 | Standard | |
| Ensembl | ENSP00000501076.1 | 2 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Lysine degradation - Homo sapiens (human)
- Histone Modifications
- Gene expression (Transcription)
- Generic Transcription Pathway
- PKMTs methylate histone lysines
Biological Process
- ovarian follicle development
- regulation of transcription by RNA polymerase II
- memory
- oocyte differentiation
- gene silencing
Molecular Function
- DNA-binding transcription factor activity, RNA polymerase II-specific
- DNA binding
- DNA-binding transcription factor activity
- protein binding
- zinc ion binding
Cellular Component
- nucleus
- nucleoplasm
- histone methyltransferase complex
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000222270
- Coding exons
- 37
- Length
- 20859
- Individuals with no LoFs
- 123835
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 7
- Defined
- 123842
- p
- 0.0000283
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 3.43 | 1209 | 1.59e+3 | 0.759 | 0.000106 | 16961 |
| Missense (PolyPhen) | 322 | 610.29 | 0.52762 | 6075 | ||
| Synonymous | -4.28 | 776 | 639 | 1.22 | 0.0000426 | 5927 |
| Loss of Function | 9.52 | 3 | 111 | 0.0269 | 0.00000640 | 1224 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0.000030 | 0.000029 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0.00014 | 0.00014 | rare |
| European (Non-Finnish) | 0.000029 | 0.000027 | rare |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Histone methyltransferase. Methylates 'Lys-4' of histone H3. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. Plays a central role in beta-globin locus transcription regulation by being recruited by NFE2. Plays an important role in controlling bulk H3K4me during oocyte growth and preimplantation development. Required during the transcriptionally active period of oocyte growth for the establishment and/or maintenance of bulk H3K4 trimethylation (H3K4me3), global transcriptional silencing that preceeds resumption of meiosis, oocyte survival and normal zygotic genome activation. {ECO:0000269|PubMed:17707229}.;
Recessive Scores
- pRec
- 0.105
Intolerance Scores
- RVIS EVS
- -5.29
- RVIS percentile EVS
- 0.06
Essentials
- Essential (CRISPR)
- N
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |